|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
CalciMedica, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
(CUSIP Number) |
Alafi Capital Company LLC 8 Admiral Drive, Suite 324, Emeryville, CA, 94608 (510) 663-7426 Christopher D. Alafi 8 Admiral Drive, Suite 324, Emeryville, CA, 94608 (510) 663-7426 Evan Ng Dorsey & Whitney LLP, 430 Cowper Street, Suite 250 Palo Alto, CA, 94301 (650) 565-2252 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
08/19/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Alafi Capital Company LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CALIFORNIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
7,220,101.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
19.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants.
The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person.
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Christopher D. Alafi | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
7,220,101.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
19.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants.
The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
CalciMedica, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
505 Coast Boulevard South Suite 307, La Jolla,
CALIFORNIA
, 92037. | |
Item 1 Comment:
The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1"). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. This Amendment No. 1 was triggered solely to reflect the issuance of warrants to the Reporting Persons on August 19, 2026. | ||
| Item 4. | Purpose of Transaction | |
None | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. | |
| (b) | See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. | |
| (c) | This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days. | |
| (d) | Not applicable. | |
| (e) | Not applicable. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|